|

QS21 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: NIAID VEU 016, Purified Quillaja Saponin, QS-21, QS-21 Adjuvant, QUILLAJA SAPONIN (QS-21) +1 more

Pipeline

Phase 1: 1

Top Sponsors

  • Ohio State University Comprehensive Cancer Center1

Indications

  • EBV-Related Malignant Neoplasm1
  • Chronic Kidney Disease, Stage 41
  • Chronic Kidney Disease Stage 51
  • Post-Transplant Lymphoproliferative Disorder1
  • EBV-Related Lymphoproliferative Disorder1

Columbus, Ohio1 trial

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

Ohio State University Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.